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Introduction
Cryopyrin-associated periodic syndrome (CAPS) is an
autoinflammatory syndrome caused by heterozygous
mutations of CIAS1/NLRP3 gene. Affected patients may
present three different phenotypes: familial cold autoin-
flammatory syndrome (FCAS), Muckle-Wells syndrome
and CINCA syndrome. Common symptoms include
sporadic or cold-induced non pruritic urticarial rash and
fever. Severe cases suffers from deafness, meningitis,
articular contracture and secondary amyloidosis.
Objectives
To describe a patients with a novel mutation associated
with an unexpected phenotype.
Methods
We describe a 13-year-old female who presented, starting
at 12 years of age, recurrent episodes of high fever, peri-
carditis, arthralgia, arthritis of the knees, abdominal pain
and marked increase in inflammatory markers (5 episodes
in the first 5 months of disease). Symptoms were poorly
responsive to therapy with NSAIDs and colchicine but
responded to steroid therapy. Molecular analysis of
MEFV, TNFR and MVK genes did not show any patho-
genic mutations. Serum amyloid level was elevated. In
the subsequent months she developed recurrent (up to
daily) episodes of chest pain, skin rash and swelling of
the subcutaneous tissue of limbs, trunk, joints and lips, in
the absence of fever, with spontaneous resolution.
Results
Molecular analysis of the CIAS1 gene revealed the pre-
sence of a c.1105C>A mutation in the heterozygous
state, that predicts a L369M amino acid substitution. To
the best of our knowledge this variant has never been
reported. One-Hundred chromosomes were examined
and the variant was not found. In the same exon, a het-
erozygous c.2107C>A nucleotide substitution, leading to
the known p.Q703K amino acid substitution has also
been detected.
We then evaluate the potential relevance of this muta-
tion on the deregulation of il1b production. Plasma IL-1b
levels were elevated compared to healthy controls. More
importantly, in vitro IL-1b production by peripheral
blood mononuclear cells, was increased; in particular, sti-
mulation with LPS alone induced detectable IL-1b in our
patient in contrast to controls. In order to verify the
potential in vivo role of the observed L369M amino acid
substitution, daily therapy with anakinra (2 mg/Kg/day)
was started with rapid disappearance of clinical symp-
toms and normalization of CRP levels in 24 hours.
Conclusion
The rapid and complete response to IL-1 inhibition sug-
gests that the clinical and laboratory features of the dis-
ease of this patient are driven by IL-1 Our data in silico,
in vitro and in vivo support the conclusion that this
novel mutation is pathogenic and may be associated
with a new CAPS phenotype. The role played by the
concomitant presence of the Q703K variant remains to
be clarified, though an effect in modifying the disease
features cannot be excluded.
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